anti-Cereblon (CRBN) Antibodies

CRBN encodes a protein related to the Lon protease protein family. Additionally we are shipping Cereblon Kits (12) and Cereblon Proteins (10) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
CRBN 297498 Q56AP7
CRBN 51185 Q96SW2
CRBN 58799 Q8C7D2
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-Cereblon Antibodies at

Showing 10 out of 45 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-CRBN Antibody Titration: 0.2-1 ug/mlPositive Control: COLO205 cell lysate 100 μL 2 to 3 Days
Human Rabbit Un-conjugated IHC, WB ABIN6272898 at 1/100 staining Human breast cancer tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. Western blot analysis of extracts of mouse heart tissue, using CRBN antibody. 100 μL 11 to 12 Days
Cow Rabbit Un-conjugated WB 100 μL 11 to 14 Days
Human Rabbit Un-conjugated IF, IHC, WB Western blot analysis of extracts of various cell lines, using CRBN antibody (ABIN1876059) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s. 100 μL 11 to 13 Days
Human Rabbit Un-conjugated ELISA, IF, IHC, IHC (p), WB Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μg 11 to 14 Days
Human Mouse Un-conjugated WB Western Blot analysis of CRBN expression in transfected 293T cell line by CRBN MaxPab polyclonal antibody.Lane 1: CRBN transfected lysate(48.62 KDa).Lane 2: Non-transfected lysate. 50 μg 11 to 12 Days
Cow Rabbit Un-conjugated WB   100 μL 2 to 3 Days
Human Rabbit Un-conjugated ELISA, IF, IHC (p), WB   0.1 mg 2 to 3 Days
Human Rabbit Un-conjugated WB Western blot analysis of extracts of various cell lines, using CRBN antibody (ABIN5972714) at 1/1000 dilution. 100 μL 11 to 16 Days
Human Rabbit Un-conjugated WB CRBN antibody used at 1 ug/ml to detect target protein. 50 μg 9 to 11 Days

Top referenced anti-Cereblon Antibodies

  1. Human Polyclonal CRBN Primary Antibody for ICC, IF - ABIN4300387 : Gandhi, Mendy, Waldman, Chen, Rychak, Miller, Gaidarova, Ren, Wang, Breider, Carmel, Mahmoudi, Jackson, Abbasian, Cathers, Schafer, Daniel, Lopez-Girona, Thakurta, Chopra: Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. in British journal of haematology 2014 (PubMed)
    Show all 7 Pubmed References

  2. Human Polyclonal CRBN Primary Antibody for WB - ABIN526543 : Charoenfuprasert, Yang, Lee, Chao, Chu, Lai, Hsu, Chang, Chen, Chen, Chang, Leu, Shih: Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. in Oncogene 2011 (PubMed)
    Show all 3 Pubmed References

More Antibodies against Cereblon Interaction Partners

Human Cereblon (CRBN) interaction partners

  1. This work suggests that the binding domain in CRBN is a critical factor which influences the regulation of immunomodulatory drugs on the ubiquitination and stability of these CRBN-interacting partners.

  2. SALL4 has a role mediating teratogenicity as a thalidomide-dependent cereblon substrate

  3. the ubiquitin-conjugating enzymes UBE2G1 and UBE2D3 cooperatively promote the K48-linked polyubiquitination of CRL4(CRBN) neomorphic substrates

  4. insight paves the way for studies of CRBN-dependent proteasome-targeting molecules in nonprimate models and provides a new understanding of CRBN's substrate-recruiting function

  5. Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner.

  6. mitochondrially expressed CRBN exhibited protease activity, and was induced by oxidative stress.

  7. we identify Rabex-5 as a Immunomodulatory drugs (IMiDs) target molecule that functions to restrain TLR activated auto-immune promoting pathways. We propose that release of Rabex-5 from complex with Cereblon enables the suppression of immune responses, contributing to the antiinflammatory properties of IMiDs.

  8. We sequenced CRBN-thalidomide binding region in 38 thalidomide embryopathy individuals and 136 Brazilians without congenital anomalies, and performed in silico analyses. Eight variants were identified, seven intronic and one in 3'UTR.

  9. These findings thus contribute to a growing list of ID disorders caused by CRBN mutations, broaden the spectrum of phenotypes attributable to Autosomal-recessive non-syndromic intellectual disability (ARNS-ID)and provide new insight into genotype-phenotype correlations between CRBN mutations and the aetiology of ARNS-ID.

  10. CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.

  11. Plasmablast differentiation, whether induced by BAFF or CD40L, is prevented by modulation of CRBN activity with CC-220, which induces degradation of the B cell differentiation factors Aiolos and Ikaros. Downregulation of these B cell differentiation processes by CC-220 modulation of CRBN provides a new therapeutic approach to treating B cell-mediated pathology in SLE.

  12. High CRBN expression is associated with multiple myeloma.

  13. CRBN negatively regulates TLR4 signaling via attenuation of TRAF6 and TAB2 ubiquitination.

  14. Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed.

  15. results suggest that CRBN binds to Ikaros via its N-terminal region and regulates transcriptional activities of Ikaros and its downstream target, enkephalin

  16. dual assay demonstrated superior Cereblon IHC measurement in MM samples compared with the single IHC assay using a published commercial rabbit polyclonal Cereblon antibody and could be used to explore the potential utility of Cereblon as a biomarker in the clinic

  17. IRF4 and CRBN polymorphisms affect risk and response to treatment in multiple myeloma

  18. overview of the current understanding of mechanism of action of Immunomodulatory drugs via CRBN and prospects for the development of new drugs that degrade protein of interest.

  19. 45.2 of multiple myeloma patients were CRBN(+). Among patients treated with thalidomide-based regimens, CRBN(+) patients showed a better treatment response than did CRBN-negative patients. There was no significant difference in survival outcomes between thalidomide- and bortezomib-based regimens in CRBN(+) patients.

  20. These results support the notion that the cereblon binding partner AGO2 plays an important role in regulating MM cell growth and survival and AGO2 could be considered as a novel drug target for overcoming IMiD resistance in MM cells.

Mouse (Murine) Cereblon (CRBN) interaction partners

  1. Crbn KO animals showed cognitive deficits caused by enhanced BK channel activity and reduced presynaptic glutamate release.

  2. We show that Crbn is robustly expressed in the mouse hippocampus and Crbn(KO) mice exhibit hyperphosphorylated levels of AMPKalpha

  3. dBET1 stimulates CRBN's E3 ubiquitin-conjugating function and degrades BRD4 in both mouse and human cells.

  4. Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner.

  5. Collectively, our data suggested that CRBN is a potential treatment option against diabetes-induced osteolytic bone disease.

  6. Data show that cereblon (CRBN) limits CD4(+) T-cell activation via epigenetic regulation of Kv1.3 potassium channel (Kv1.3) expression.

  7. CRBN negatively regulates TLR4 signaling via attenuation of TRAF6 and TAB2 ubiquitination.

  8. CRBN is involved in the activation of PERK and the Ire1 pathway of the unfolded protein response.CRBN plays a role in cellular stress signaling, including the unfolded protein response, by controlling the activity of AMPK.

  9. results of this study suggest a plausible mechanism for CRBN involvement in higher brain function in humans, and they may help explain how a specific mutation in CRBN can affect the cognitive ability of patients

  10. Found significantly smaller infarct sizes and less fibrosis in the hearts of CRBN KO mice than in those of WT mice. Apoptosis was also significantly reduced in the KO mice compared with that in WT mice.

  11. findings suggest that crbn-/- mice exhibit selective HPC-dependent deficits in associative learning.

  12. CRBN directly interacts with the alpha1 subunit of AMP-activated protein kinase (AMPK alpha1) and inhibits the activation of AMPK activation.

  13. These results imply that Nrf2 stimulates CRBN gene transcription under hypoxia-reoxygenation conditions in neuronal cells.

Cereblon (CRBN) Antigen Profile

Protein Summary

This gene encodes a protein related to the Lon protease protein family. In rodents and other mammals this gene product is found in the cytoplasm localized with a calcium channel membrane protein, and is thought to play a role in brain development. Mutations in this gene are associated with autosomal recessive nonsyndromic mental retardation. Multiple transcript variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with anti-Cereblon (CRBN) Antibodies

  • cereblon (crbn) antibody
  • cereblon (CRBN) antibody
  • ATP-dependent protease La (LON) domain protein (AT2G25740) antibody
  • cereblon (Crbn) antibody
  • 2610203G15Rik antibody
  • 2900045O07Rik antibody
  • AF229032 antibody
  • AW108261 antibody
  • F3N11.21 antibody
  • MRT2 antibody
  • MRT2A antibody
  • piL antibody
  • zgc:92404 antibody

Protein level used designations for anti-Cereblon (CRBN) Antibodies

protein cereblon , zcrbn , cereblon , protein cereblon-like , protein x 0001 , novel lethal , protein PiL , Protein cereblon

445491 Danio rerio
100052958 Equus caballus
704436 Macaca mulatta
460130 Pan troglodytes
493554 Xenopus (Silurana) tropicalis
100022278 Monodelphis domestica
100479474 Ailuropoda melanoleuca
817117 Arabidopsis thaliana
100584605 Nomascus leucogenys
297498 Rattus norvegicus
51185 Homo sapiens
58799 Mus musculus
511585 Bos taurus
416104 Gallus gallus
476551 Canis lupus familiaris
100174633 Pongo abelii
Selected quality suppliers for anti-Cereblon (CRBN) Antibodies
Did you look for something else?